1. Background {#sec1-1}
=============

Type I diabetes mellitus (TIDM) is an autoimmune disease that involves the immunological destruction of the insulin producing islets of Langerhans. Pancreatic islet transplantation is one of the most promising strategies for these patients ([@ref1],[@ref2]). However, this strategy is limited due to the side effects of the immune suppressive drugs that should be taken by the recipients to overcome the host immunological responses, especially in xenotransplantation ([@ref3],[@ref4]). To avoid the host-rejection, in addition to decreasing the risk of immunosuppressive drugs, immuno-isolation systems including microencapsulation for the islets of Langerhans ([@ref5]) and surface modification by polyethylene glycol (PEG) (PEGylation) for pancreatic islets ([@ref10]), have been developed.

Several reactive derivatives of methoxy polyethylene glycol (mPEG) have been used for cell PEGylation. In our previous work, red blood cells (RBCs) were PEGylated by mPEG-succinimdyl valerate (mPEG-SVA) and mPEG-succinimidyl carbonate (mPEG-SC), separately. The results showed that mPEG-SVA was more effective ([@ref13]).

Additionally, Aghajani-Lazarjani *et al.* optimized islets PEGylation using mPEG-SPA. The factors of reaction time, the ratio of longer polymer in the mixture of mPEGs, and polymer concentration were considered ([@ref14]). In another study involving islet PEGylation using mPEG-succinimdyl propionic acid (mPEG-SPA) and mPEG-SC, separately, it was shown a better immunological protection using mPEG-SC ([@ref10]). As well, in our previous study (the data not shown) the results showed that mPEG-SVA had more efficiency than mPEG-SC to protect the islets from the immune system.

Pancreatic islets may also be encapsulated in the semi-permeable membranes. The membranes are designed to allow diffusion of the glucose and insulin but prevent immunological intermediates ([@ref5]).

Several studies have so far been presented on the properties of the different materials for encapsulation such as chitosan, which is a natural polymer obtained from chitin after N-deacetylation by alkaline treatment. Chitosan is non toxic, biocompatible, and has antimicrobial properties ([@ref15]). Alginate-poly-L-lysine (PLL) capsules for pancreatic islets were introduced by Lim and Sun ([@ref8]). In addition, many researchers have investigated encapsulation using different polycations such as chitosan and poly-L-ornithine (PLO). Azadi *et al*, have used dextran-spermine as a polycation together with alginate as a polyanion for co-encapsulation of pancreatic islets and pentoxifylline as an immunosuppressive drug to develop a cell therapy system for the possible treatment of insulin dependent diabetes mellitus ([@ref16]).

Encapsulation containing three layers is a more protective immunoisolation system. However, these three layers increase the total volume of the microcapsules. In our previous study ([@ref17]), we introduced a novel immunoisolation system with three layers, using a combination of encapsulation and PEGylation containing alginate-PLO-mPEG that reduces the microcapsules' volume in comparison to the previous three layer encapsulations. **[Figure 1](#fig001){ref-type="fig"}** shows a schematic picture of the islet encapsulation, PEGylation and also, a combination of PEGylation and encapsulation.

2. Objectives {#sec1-2}
=============

In the present study, the immunoisolation properties of the multilayer encapsulated islets using alginate-chitosan-PEG was investigated for immunoprotection and insulin secretion from the encapsulated islets induced under different glucose concentrations.

3. Materials and Methods {#sec1-3}
========================

3.1. Materials {#sec2-1}
--------------

mPEG-SVA of 5 and 10 kDa were purchased from Lysan Bio Inc. Chitosan (85% deacetylation), propidium iodide (PI) and HEPES were obtained from Sigma Aldrich. RPMI-1640 medium, fetal bovine serum (FBS), non-essential amino acid solution (MEM), and penicillin/streptomycin antibiotics were purchased from GIBCO. Alginate with high G block content was obtained from BDH. Bovine serum albumin (BSA) and acridine orange (AO) were purchased from Merck. Mouse IL-2 kit was obtained from Ebioscience (San Diego, CA, USA). Insulin ultrasensitive kit and collagenase P were purchased from Mercodia and Roche, respectively.

3.2. Islet Isolation {#sec2-2}
--------------------

Following 16 h fasting, adult male Wistar rats (170-190 g, 2.5-3.0 months old), were anesthetized and their abdomen was opened. Briefly, according to the previous study in our group 10 mL of collagenase (0.5 mg.mL^-1^) in HBSS was gently injected into the common bile duct. The inflated pancreas was incubated in water bath at 37 °C for 17 min and then the digestion process was terminated using cold Hanks solution. The tube was shaken for 1 min and the obtained suspension was filtered (using 200 µm filter) into a glass container. The supernatant was removed, a process which was repeated three times. After the last aspiration, the islets were handpicked (all steps were performed on ice) ([@ref10]).

3.3. PEGylation of the Islets {#sec2-3}
-----------------------------

According to our previous work ([@ref17]), a group of the isolated islets was handpicked and suspended in the Hanks solution (30 islets.mL^-1^) and mixed with a mixture of 5 kDa mPEG-SVA (25%) and 10 kDa mPEG-SVA (75%). Then, they were incubated at 37 °C and 5% CO~2~ condition for 60 min. After washing the PEGylated islets, they were investigated for insulin secretion according to the following sections (all steps were performed on ice).

3.4. Encapsulation of the Islets Using Alginate Chitosan-PEG {#sec2-4}
------------------------------------------------------------

A group of the isolated islets were suspended in alginate solution (2% w/v containing 2 g alginate in 100 mL normal saline) (30 islets.mL^-1^). Then, using a syringe pump and encapsulator device, it was dropped (7 mL.min^-1^) into CaCl~2~ solution (100 mM) in which the hydrogel was constructed. The obtained microcapsules remained in CaCl~2~ solution for 15-30 min. The encapsulated islets were then suspended in chitosan solution (1% w/v containing 0.1 g chitosan dissolved in 10 mL acetic acid 0.1 N) for 15 min. The microcapsules were then diluted in mPEG-SVA solution (0.1% w/v) in Hanks' balanced salt solution (HBSS, pH 8) for 30 min (all of the steps were performed on the ice) ([@ref18]). After washing, the encapsulated islets they were investigated for the insulin secretion and immunological reactions according to the following sections.

3.5. Leukocytes Isolation {#sec2-5}
-------------------------

The leukocytes were isolated from male C57BL/6 mice (12 weeks, 25-30 g), according to the previous work in our group ([@ref10]).

### 3.5.1. Immunological Reactions Investigation {#sec3-1}

The immunological reactions were investigated by co-culturing 12-16 encapsulated or free islets (without any coating, as control) with 2 ×10^5^ leukocytes, according to our previous work ([@ref18]).

### 3.5.2. Glucose-Stimulated Insulin Secretion {#sec3-2}

Glucose-stimulated insulin secretion was assessed at two glucose concentrations (5.6 and 16.7 mM) for 3 groups of the isolated islets (islets without any coating (as control), encapsulated islets, and PEGylated islets), separately. For each glucose concentration, 8 replications of 4 islets were randomly selected and placed in 24-well plates. Two milliliter of Krebs Ringer solution \[117 mmoL.L^-1^ NaCl, 2.5 mmoL.L^-1^ CaCl~2~, 1.2 mmoL.L^-1^ KH~2~PO~2~, 1.2 mmoL.L^-1^ MgSO~4~, and 24.6 mmoL.L^-1^ NaHCO~3~, (pH 7.4), BSA 0.5 g.dL^-1^\] containing 5.6 or 16.7 mM glucose was added to each well and incubated at 37 °C and 5% CO~2~ for 60 min. After 30 and 60 min, 500 µL of the supernatant was sampled from each well and stored at -70 °C for insulin analysis ([@ref10], [@ref19]). The amount of insulin secreted by the islets in all groups and under two different glucose concentrations, were measured using rat insulin Elisa kit ([@ref19]).

3.6. Viability Test {#sec2-6}
-------------------

Viability of the islets was assessed by microscopic examination using AO-PI staining in each group after 60 min incubation in glucose solution. The islets were exposed to 50 µL AO and 950 µL PI in 1 mL incubation solution and evaluated using the fluorescence microscope (Nikon, Japan). The viable and dead cells were identified as green- and red-colored, respectively ([@ref10]).

3.7. Statistical Analysis {#sec2-7}
-------------------------

Statistical analysis was carried out using PRISM version 5.0 program package with data expressed as mean ± SEM. Two-way ANOVA followed by Bonferroni test were used to analyze the difference between the groups. P-value less than 0.05 was considered statistically significant.

4. Results {#sec1-4}
==========

4.1. The Effects of Encapsulation and PEGylation on the Islet Viability {#sec2-8}
-----------------------------------------------------------------------

The isolated islets were PEGylated and encapsulated, in separated groups, according to sections 3.3 and 3.4, and their viability were investigated. As it can be seen in **[Figure 2](#fig002){ref-type="fig"}**, the PEGylated, encapsulated, and control islets, incubated in Krebs Ringer solution (pH 7.4) containing 5.6 or 16.7 mM glucose, respectively, were viable after 60 min incubation.

4.2. The Effects of Islet Immuno-isolation {#sec2-9}
------------------------------------------

The amounts of IL-2 secreted from the co-cultured lymphocytes with the encapsulated islets in alginate-chitosan-PEG are presented in [Figure 3](#fig003){ref-type="fig"}. According to the results, the amount of IL-2 secretion from the co-cultured lymphocytes with the encapsulated islets after 7 days is approximately 38% lower than that of co-cultured lymphocytes with the free islets. The immunoprotection of PEGylated islets has also been investigated in another study where it has shown a decrease in the IL-2 secretion in comparison to the free islets, as well ([@ref17]).

4.3. The Effect of PEGylation and Encapsulation on Insulin Secretion {#sec2-10}
--------------------------------------------------------------------

According to section 3.7, glucose-stimulated insulin secretion was assessed at two glucose concentrations (5.6 and 16.7 mM) for 3 groups of the isolated islets. Insulin secretion from the PEGylated, encapsulated, and control groups are shown in **[Figure 4](#fig004){ref-type="fig"}**. In the presence of 16.7 mM glucose, insulin secretion from the PEGylated and encapsulated groups were significantly (*p* \< 0.001) higher than that of 5.6 mM after 30 and 60 min incubation. Also, the PEGylated and encapsulated groups secreted insulin similar to the control group at 30 and 60 min (approximately 2.5-3.0 folds higher for 16.7 mM in all groups). Two-way ANOVA showed no significant differences between insulin secretions from the PEGylated and encapsulated with control islets induced when glucose at 5.6 and 16.7 mM concentrations were used after 30 and 60 min, respectively. The trends in insulin secretion from the PEGylated and encapsulated islets were similar to the control group.

5. Discussion {#sec1-5}
=============

The present study shows the effect of islets encapsulation in the alginate-chitosan-PEG on IL-2 secretion by lymphocytes co-cultured with islets as well as insulin secretion by the encapsulated islets. In the previous studies, Aghajani-Lazarjani *et al.* ([@ref10]) have reported the efficiency of mPEG-SPA and mPEG-SC as immunoisolation systems and showed that both activated mPEGs can protect islets from the host immune system. They showed that mPEG-SC is more desirable than mPEG-SPA due to its easier synthesis process. Schneider *et al.* ([@ref20]) have shown that two layers of the microcapsules using alginate and chitosan can decrease IL-2 secretion and the host's immune stimulation compared to alginate microcapsules. In the previous study ([@ref18]) We showed 61.9% decrease in the IL-2 secretion against the encapsulated islets in the alginate-PLO-mPEG-SVA as a novel immunoisolation system using a combination of two different methods of the encapsulation and PEGylation compared to the free islets. The results of the present study show that islets encapsulated in the alginate-chitosan-mPEG-SVA as an immunoisolation system, co-cultured with the lymphocytes, significantly decreases IL-2 secretion from lymphocytes; about 38% less than that co-cultured with the free islets, under the same condition. Also, the viability test showed that the three layer encapsulated islets do not damage the islets as all the islets were alive after encapsulation process.

The immunoisolation systems in addition to protection of the islets against the host immune system should also support their natural functions. This indicates that immunoisolation systems should prepare enough space to transfer glucose, insulin, and other essential nutrients. Korbutt *et al* ([@ref21]) induced alginate-encapsulated islets at two different glucose concentrations; at 2.8 mM and 16.7 mM, respectively. Their results showed that the alginate capsules had no effect on insulin secretion from the encapsulated islets. Thus, the encapsulated islets can sense glucose as well as control islets. Also, Schneider *et al* ([@ref20]) showed that encapsulated islets using alginate-chitosan for encapsulation can release insulin at different glucose concentration; exactly similar to the control islets. Panza *et al* ([@ref2]) considered the efficiency of PEG-isocyanate as an immunoisolation system for the islets and reported that the islets in PEG-isocyanate, in addition to stability, can respond to different glucose concentrations. Aghajani-Lazarjani *et al* ([@ref10]) exposed the PEGylated islets with mPEG-SPA and mPEG-SC to the different glucose concentrations separately in order to investigate islets function and showed that islets can sensitively respond to the glucose concentrations and release of insulin exactly similar to the free islets. They reported that the difference between insulin secretion from the PEGylated and the free islets was not significant after 60 min incubation.

In the present study, to investigate the performance of islets encapsulated in either alginate-chitosan-mPEG or PEGylated with the mPEG-SVA and in the presence of different glucose concentrations, the amount of insulin secreted from the islets was measured. The PEGylated islets using mPEG-SVA and encapsulated islets in the alginate-chitosan-mPEG exposed to different glucose concentrations could respond to the glucose concentration and release insulin exactly similar to the PEGylated islets with mPEG-SPA and mPEG-SC and retain their biological function. Also, glucose sensitivity for all of the three groups (control, PEGylated with mPEG SVA and encapsulated in alginate-chitosan-mPEG SVA) were similar to each other and could release insulin depending on the sensed glucose concentrations (16.7 and 5.6 mM) after 30 and 60 min. It was shown that three layers of alginate-chitosan-mPEG-SVA have enough space to transfer the essential nutrients as well as insulin. On the other hand, the immune test showed that this kind of immunoisolation system could protect the islets against the host immune system.

6. Conclusions {#sec1-6}
==============

The present study has investigated the effect of encapsulation and PEGylation on the glucose sensitivity of the isolated islets in addition to the insulin release from the encapsulated, PEGylated, and free islets. Insulin release from all of the groups showed that encapsulation and PEGylation have no negative effect on the insulin secretion and glucose sensitivity of the isolated islets. Therefore, these two immunoprotective methods cannot affect the natural function of the islets of Langerhans. Also, it was found that the encapsulated islets in the alginate-chitosan-mPEG-SVA, as an immunoisolation system co-cultured with lymphocytes, have significantly decreased IL-2 secretion from the lymphocytes at about 38% less than that of co-cultured with the free islets under the same condition.

![A schematic drawing of (a) PEGylation, (b) encapsulation, and (c) a combination of encapsulation and PEGylation.](ijb-2018-04-e1669-g001){#fig001}

![The viability (using AO-PI staining) of the control and PEGylated islets: the viable (a) and control (b) PEGylated islets incubated in the Krebs Ringer solution (pH 7.4) containing 5.6 mM glucose after 60 min incubation. (c) control and (d) PEGylated islets incubated in the Krebs Ringer solution (pH 7.4) containing 16.7 mM glucose after 60 min incubation. (e) control and (f) encapsulated islets incubated in the Krebs Ringer solution (pH 7.4) containing 5.6 mM glucose after 60 min incubation, and (g) control and (h) the encapsulated islets incubated in the Krebs Ringer solution (pH 7.4) containing 16.7 mM glucose after 60 min incubation.](ijb-2018-04-e1669-g002){#fig002}

![The amount of secreted IL-2 from lymphocytes co-cultured with the islets (\*\*\* shows the significant differences).](ijb-2018-04-e1669-g003){#fig003}

![Insulin secretion (pmol/islet.time) from the PEGylated and encapsulated groups compared to the naked islets group in the presence of 5.6 and 16.7 mM glucose concentrations: (![](ijb-2018-04-e1669-i001.jpg) Naked islets at 5.6 mM glucose, ![](ijb-2018-04-e1669-i002.jpg) naked islets at 16.7 mM glucose, ![](ijb-2018-04-e1669-i003.jpg) PEGylated islets at 5.6 mM glucose, ![](ijb-2018-04-e1669-i004.jpg) PEGylated islets at 16.7 mM glucose, ![](ijb-2018-04-e1669-i005.jpg) encapsulated islets at 5.6 mM glucose, and ![](ijb-2018-04-e1669-i006.jpg) encapsulated islets at 16.7 mM glucose) (\*\*\* shows the significant difference between insulin secretion in the presence of 16.7 mM and 5.6 mM glucose).](ijb-2018-04-e1669-g004){#fig004}
